We use cookies to customise content for your subscription and for analytics.
If you continue to browse Lexology, we will assume that you are happy to receive all our cookies. For further information please read our Cookie Policy.

Search results

Order by: most recent most popular relevance

Results: 1-10 of 160

Pre-revenue Biotech Companies Can Apply For Listing In Hong Kong With Effect From 30 April 2018
  • Baker McKenzie
  • Hong Kong
  • April 26 2018

On 24 April 2018, The Stock Exchange of Hong Kong Limited (HKEx) published its Consultation Conclusions to HKEx's proposals to expand Hong Kong's

Hong Kong Announces Groundbreaking New Rules for Dual-Class Share, High-Tech and Biotech Company Listings
  • Skadden Arps Slate Meagher & Flom LLP
  • Hong Kong
  • February 26 2018

After publishing the “New Board Concept Paper Conclusions” in December 2017, the Stock Exchange of Hong Kong Limited (the Exchange) issued on 23

Roy G. Zou
  • Hogan Lovells

Antony Dapiran
  • Skadden Arps Slate Meagher & Flom LLP

Zhen (Katie) Feng
  • Hogan Lovells

Nick Akerman
  • Dorsey & Whitney LLP

Deanna Wong
  • Hogan Lovells

Helen Clark
  • Locke Lord LLP

David Erickson
  • Shook Hardy & Bacon LLP